A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients

Treatment Patterns and Real World Effectiveness of Standard of Care in Primary Immune Thrombocytopenia (ITP) Patients: A Real-world Retrospective Cohort Study Using the Optum® Market Clarity Database

The aim of this study was to describe real-world treatment patterns and standard of care treatment effectiveness and utilization outcomes in adult primary ITP patients indicated for second-line treatment with any prior corticosteroid treatment in real-world treatment settings in the United States (US) identified in an electronic health record (EHR) and claims database.

Inclusion criteria

1. Evidence of a diagnosis of primary ITP during the study identification period.
2. Evidence of treatment with any allowed second-line treatment during the study identification period after the first primary ITP diagnosis.
3. Evidence of treatment with any allowed first-line treatment prior to index.
4. Aged ≥18 years at index.

Exclusion criteria

1. Fewer than 12 months continuous enrollment or activity prior to index.
2. Fewer than one inpatient or fewer than two outpatient records during baseline.
3. Evidence of any allowed second-line therapies or splenectomy prior to index.
4. Evidence of diagnosis of Evans syndrome, systemic lupus erythematosus, autoimmune lymphoproliferative syndrome, human immunodeficiency virus (HIV), hepatitis C virus (HCV), Helicobacter pylori, Sjogren's antiphospholipid syndrome prior to index, or active b-cell malignancies (not in remission) in the baseline period.
5. Continuous enrollment end date or death date prior to index.